4
Changes in Ownership
Avalo Therapeutics, Inc. Filed Acc 0001918845-26-000004
Chief Medical Officer sold 25,492 shares at $16.15 ($411,607)
- Chief Medical Officer acquired 25,492 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Doyle Mittie · Chief Medical Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-16 | Exercise or conversion : show line 1 in the form 10b5-1 | +19,500 | $12.65 | $246,675 | 23,122 | D |
| 2026-03-16 | Exercise or conversion : show line 2 in the form 10b5-1 | +5,992 | $8.04 | $48,176 | 29,114 | D |
| 2026-03-16 | Sale : show line 3 in the form 10b5-1 | −25,492 | $16.15 | $411,607 | 3,622 | D |
| Open-market sales · 25,492 sh · avg $16.15 · $411,607 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-16 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) | −19,500 | 214,500 | D |
| 2026-03-16 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) | −5,992 | 149,008 | D |
Loading xslF345X06/form4-03182026_080310.xml…